Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Evens

Showing results (231-240 of 253) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816Oliver W Press, Hongli Li, Heiko Schöder, et al.
Blood|September 8, 2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experienceAnthony R Mato, Chadi Nabhan, Paul M Barr, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World ExperienceMuhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
American Journal of Hematology|June 6, 2015
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohortAndrew M Evens, Jennifer A Kanakry, Laurie H Sehn, et al.
Blood Advances|August 21, 2023
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphomaRaphael E Steiner, Steven R Hwang, Arushi Khurana, et al.
British Journal of Haematology|December 22, 2018
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphomaBrian T Hill, Loretta Nastoupil, Allison M Winter, et al.
Blood Cancer Journal|August 7, 2024
Identification of genetic subtypes in follicular lymphomaVictoria Shelton, Rajesh Detroja, Ting Liu, et al.
Blood Advances|September 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent eraSanjal H Desai, Michael A Spinner, Andrew M Evens, et al.
Blood Cancer Journal|June 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Susan M Geyer, Levi Pederson, et al.
Nature Genetics|November 13, 2012
The genetic landscape of mutations in Burkitt lymphomaCassandra Love, Zhen Sun, Dereje Jima, et al.
Pageof 26

Showing results (231-240 of 253) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816Oliver W Press, Hongli Li, Heiko Schöder, et al.
Blood|September 8, 2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experienceAnthony R Mato, Chadi Nabhan, Paul M Barr, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World ExperienceMuhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
American Journal of Hematology|June 6, 2015
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohortAndrew M Evens, Jennifer A Kanakry, Laurie H Sehn, et al.
Blood Advances|August 21, 2023
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphomaRaphael E Steiner, Steven R Hwang, Arushi Khurana, et al.
British Journal of Haematology|December 22, 2018
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphomaBrian T Hill, Loretta Nastoupil, Allison M Winter, et al.
Blood Cancer Journal|August 7, 2024
Identification of genetic subtypes in follicular lymphomaVictoria Shelton, Rajesh Detroja, Ting Liu, et al.
Blood Advances|September 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent eraSanjal H Desai, Michael A Spinner, Andrew M Evens, et al.
Blood Cancer Journal|June 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Susan M Geyer, Levi Pederson, et al.
Nature Genetics|November 13, 2012
The genetic landscape of mutations in Burkitt lymphomaCassandra Love, Zhen Sun, Dereje Jima, et al.
Pageof 26